What are the top 3 AI investments for clinical development leaders?

Improving current tools, such as faster drafting platforms, advanced interfaces, and improved analytics, is not sufficient. What companies in R&D now want from these advancements is a complete redesign of the way clinical development operates. For this reason (among many others), the pharmaceutical industry is undergoing a major transformation through the use of artificial intelligence (AI), replacing replace long-standing development processes with dynamic and efficient practices.

AI in clinical trials: Reflecting on recent progress

Pharma companies have increasingly adopted AI tools for document authoring, feasibility assessments, risk identification, and data automation. However, many of these initiatives have stalled at the proof-of-concept stage, showing promise in controlled environments but rarely scaling into full production. Looking ahead, orchestration is becoming the defining priority, and this is where clinical research consulting plays a critical role. 

Clinical development must be treated as an interconnected system of decisions spanning protocol design, trial execution, and regulatory submission, where AI continuously senses, predicts, and guides action.

Exploring the impact of three investments on system performance

Scaling AI-Powered clinical document authoring

Clinical documentation remains one of the most time-intensive bottlenecks in drug development. A single trial can require more than 90 documents, each taking days or even months to reach a reviewable draft, translating to hundreds of authoring days annually.

Early deployments of integrated authoring platforms show that 75%–90% of first drafts are review-ready, matching or exceeding human-written quality on key measures of accuracy and consistency. Over time, each approved document strengthens the system, driving 30%–60% faster authoring cycles and reducing review timelines for complex documents from 8 to 14 weeks down to roughly 2 to 6 weeks. The outcome is not merely faster writing, it also means reduced review burdens, accelerated trial timelines, and greater focus on scientific rigor.

Reimagining protocol design through AI simulation

AI-driven systems are already reducing protocol design cycles by a good extent, resulting in fewer late-stage amendments and stronger alignment with original trial plans. The shift now is from precedent-driven workflows to systems that actively simulate what a trial will encounter before it begins. 

AI agents representing clinical, statistical, regulatory, and patient perspectives can evaluate proposed designs simultaneously. Each agent can surface opinions on endpoints, eligibility criteria, and execution feasibility while drawing on the data most relevant to its role. This allows teams to identify trade-offs early and resolve disagreements during the design phase rather than through costly amendment cycles.

Building predictive portfolio visibility

Fewer than 20% of trials meet their original enrollment goals. More than 70% face startup delays, and over 30% of patients drop out, with each replacement costing significantly more to recruit. These are not isolated execution failures; they are systemic signals that often go undetected until intervention becomes expensive.

Predictive visibility at the portfolio level changes this equation. By harmonizing data across clinical, quality, safety, and operational systems, leadership teams can shift from retrospective performance reviews to proactive risk management. This helps identifying issues such as site underperformance, declining screening rates, or rising screen failures before they escalate into timeline delays. 

Effective customer experience consulting principles apply here, ensuring that every stakeholder, from site teams to executive leadership, receives timely, relevant insights that support confident decision-making.

When AI capabilities are connected and built on strong data foundations, development costs could fall by up to 60%, while trial cycle times could shorten by up to 40%. The transformation is already underway; the only question is who will lead it.